Peak Asset Management LLC Purchases Shares of 2,454 IQVIA Holdings Inc. $IQV

Peak Asset Management LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,454 shares of the medical research company’s stock, valued at approximately $474,000.

Other institutional investors also recently modified their holdings of the company. L2 Asset Management LLC acquired a new stake in IQVIA during the 2nd quarter valued at $1,942,000. Vega Investment Solutions acquired a new stake in IQVIA in the 2nd quarter valued at about $709,000. SaddleRock Capital Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $9,551,000. Ally Financial Inc. acquired a new position in IQVIA during the 2nd quarter valued at about $1,063,000. Finally, Cibc World Market Inc. bought a new stake in shares of IQVIA during the 2nd quarter valued at $11,294,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.2%

NYSE IQV opened at $260.30 on Tuesday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $261.88. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.85 billion, a P/E ratio of 32.30, a P/E/G ratio of 2.21 and a beta of 1.18. The business has a 50 day simple moving average of $214.97 and a 200 day simple moving average of $187.62.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Royal Bank Of Canada boosted their target price on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Morgan Stanley restated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. BMO Capital Markets upped their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Finally, TD Cowen raised their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $241.88.

Insider Activity

In other news, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last quarter. 1.70% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.